{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 0, "source_chunk_idxs": [0], "num_tokens": 487, "text": "Frontiers | Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nFrontiers in Dementia\nAbout us\nAbout us\n- Who we are\n- Mission and values\n- History\n- Leadership\n- Awards\n- Impact and progress\n- Frontiers' impact\n- Our annual reports\n- Publishing model\n- How we publish\n- Open access\n- Peer review\n- Research integrity\n- Research Topics\n- FAIR\u00b2 Data Management\n- Fee policy\n- Services\n- Societies\n- National consortia\n- Institutional partnerships\n- Collaborators\n- More from Frontiers\n- Frontiers Forum\n- Frontiers Planet Prize\n- Press office\n- Sustainability\n- Career opportunities\n- Contact us\nAll journals\nAll articles\nSubmit your research\nSearch\nFrontiers in Dementia\nSections\nSections\n- Aging and Risk Factors for Dementia\n- Cellular and Molecular Mechanisms of Dementia\n- Dementia Care\n- Genetics and Biomarkers of Dementia\n- Imaging and Diagnostic tools for Dementia\n- Translational Research in Dementia\nArticles\nResearch Topics\nEditorial board\nAbout journal\nAbout journal\n- Scope\n- Field chief editors\n- Mission &amp; scope\n- Facts\n- Journal sections\n- Open access statement\n- Copyright statement\n- Quality\n- For authors\n- Why submit?\n- Article types\n- Author guidelines\n- Editor guidelines\n- Publishing fees\n- Submission checklist\n- Contact editorial office\nAbout us\nAbout us\n- Who we are\n- Mission and values\n- History\n- Leadership\n- Awards\n- Impact and progress\n- Frontiers' impact\n- Our annual reports\n- Publishing model\n- How we publish\n- Open access\n- Peer review\n- Research integrity\n- Research Topics\n- FAIR\u00b2 Data Management\n- Fee policy\n- Services\n- Societies\n- National consortia\n- Institutional partnerships\n- Collaborators\n- More from Frontiers\n- Frontiers Forum\n- Frontiers Planet Prize\n- Press office\n- Sustainability\n- Career opportunities\n- Contact us\nAll journals\nAll articles\nSubmit your research\nFrontiers in Dementia\nSections\nSections\n- Aging and Risk Factors for Dementia\n- Cellular and Molecular Mechanisms of Dementia\n- Dementia Care\n- Genetics and Biomarkers of Dementia\n- Imaging and Diagnostic tools for Dementia\n- Translational Research in Dementia\nArticles\nResearch Topics\nEditorial board\nAbout journal\nAbout journal\n- Scope\n- Field chief editors\n- Mission &amp; scope\n- Facts\n- Journal sections\n- Open access statement\n- Copyright statement\n- Quality\n- For authors\n- Why submit?\n- Article types\n- Author guidelines\n- Editor guidelines\n- Publishing fees\n- Submission checklist\n- Contact editorial office\nFrontiers in Dementia\nSections\nSections\n- Aging and Risk Factors for Dementia\n- Cellular and Molecular Mechanisms of Dementia\n- Dementia Care\n- Genetics and Biomarkers of Dementia\n- Imaging and Diagnostic tools for Dementia\n- Translational Research in Dementia\nArticles\nResearch Topics\nEditorial board\nAbout journal\nAbout journal", "doc_items_refs": ["#/texts/1", "#/texts/2", "#/texts/3", "#/texts/4", "#/texts/5", "#/texts/6", "#/texts/7", "#/texts/8", "#/texts/9", "#/texts/10", "#/texts/11", "#/texts/12", "#/texts/13", "#/texts/14", "#/texts/15", "#/texts/16", "#/texts/17", "#/texts/18", "#/texts/19", "#/texts/20", "#/texts/21", "#/texts/22", "#/texts/23", "#/texts/24", "#/texts/25", "#/texts/26", "#/texts/27", "#/texts/28", "#/texts/29", "#/texts/30", "#/texts/31", "#/texts/32", "#/texts/33", "#/texts/34", "#/texts/35", "#/texts/36", "#/texts/37", "#/texts/38", "#/texts/39", "#/texts/40", "#/texts/41", "#/texts/42", "#/texts/43", "#/texts/44", "#/texts/45", "#/texts/46", "#/texts/47", "#/texts/48", "#/texts/49", "#/texts/50", "#/texts/51", "#/texts/52", "#/texts/53", "#/texts/54", "#/texts/55", "#/texts/56", "#/texts/57", "#/texts/58", "#/texts/59", "#/texts/60", "#/texts/61", "#/texts/62", "#/texts/63", "#/texts/64", "#/texts/65", "#/texts/66", "#/texts/67", "#/texts/68", "#/texts/69", "#/texts/70", "#/texts/71", "#/texts/72", "#/texts/73", "#/texts/74", "#/texts/75", "#/texts/76", "#/texts/77", "#/texts/78", "#/texts/79", "#/texts/80", "#/texts/81", "#/texts/82", "#/texts/83", "#/texts/84", "#/texts/85", "#/texts/86", "#/texts/87", "#/texts/88", "#/texts/89", "#/texts/90", "#/texts/91", "#/texts/92", "#/texts/93", "#/texts/94", "#/texts/95", "#/texts/96", "#/texts/97", "#/texts/98", "#/texts/99", "#/texts/100", "#/texts/101", "#/texts/102", "#/texts/103", "#/texts/104", "#/texts/105", "#/texts/106", "#/texts/107", "#/texts/108", "#/texts/109", "#/texts/110", "#/texts/111", "#/texts/112", "#/texts/113", "#/texts/114", "#/texts/115", "#/texts/116", "#/texts/117", "#/texts/118", "#/texts/119", "#/texts/120", "#/texts/121", "#/texts/122", "#/texts/123", "#/texts/124", "#/texts/125", "#/texts/126", "#/texts/127", "#/texts/128", "#/texts/129", "#/texts/130", "#/texts/131", "#/texts/132", "#/texts/133", "#/texts/134", "#/texts/135", "#/texts/136", "#/texts/137", "#/texts/138", "#/texts/139", "#/texts/140", "#/texts/141", "#/texts/142"], "page_nos": [], "uuid": "591975a0-afa2-4560-921e-d90b651553c3"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 1, "source_chunk_idxs": [1, 2], "num_tokens": 440, "text": "Frontiers | Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n- Scope\n- Field chief editors\n- Mission &amp; scope\n- Facts\n- Journal sections\n- Open access statement\n- Copyright statement\n- Quality\n- For authors\n- Why submit?\n- Article types\n- Author guidelines\n- Editor guidelines\n- Publishing fees\n- Submission checklist\n- Contact editorial office\nSubmit your research\nSearch\nYour new experience awaits. Try the new design now and help us make it even better\nSwitch to the new experience\nMINI REVIEW article\nFront. Dement. , 04 August 2025\nSec. Translational Research in Dementia\nVolume 4 - 2025 |\nhttps://doi.org/10.3389/frdem.2025.1605051\nThis article is part of the Research Topic Studying Dementia in 3D: Basic Techniques and Applications\nView all 3 articles\n\nPsychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nXenia Androni\n1\nRachel J. Boyd\n1,2,3\nPaul B. Rosenberg\n3,4\nVasiliki Mahairaki\n1,3 *\n- 1\nDepartment of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States\n- 2\nDivision of Geriatric Medicine and Gerontology, Johns Hopkins School of Medicine, Baltimore, MD, United States\n- 3\nThe Richman Family Precision Medicine Center of Excellence in Alzheimer's Disease, Johns Hopkins School of Medicine, Baltimore, MD, United States\n- 4\nDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, MD, United States\nAlzheimer's disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia. Recent advances in psychedelic research underscore numerous neuroplastogenic and anti-inflammatory alterations induced by these compounds, making them promising therapeutic candidates for AD. In this mini review, we will briefly summarize the existing literature using human cerebral organoids to study the molecular and metabolic changes caused by various psychedelic compounds, focusing on their potential therapeutic applications for AD.", "doc_items_refs": ["#/texts/143", "#/texts/144", "#/texts/145", "#/texts/146", "#/texts/147", "#/texts/148", "#/texts/149", "#/texts/150", "#/texts/151", "#/texts/152", "#/texts/153", "#/texts/154", "#/texts/155", "#/texts/156", "#/texts/157", "#/texts/158", "#/texts/159", "#/texts/160", "#/texts/161", "#/texts/162", "#/texts/163", "#/texts/164", "#/texts/165", "#/texts/166", "#/texts/167", "#/texts/168", "#/texts/169", "#/texts/171", "#/texts/172", "#/texts/173", "#/texts/174", "#/texts/175", "#/texts/176", "#/texts/177", "#/texts/178", "#/texts/179", "#/texts/180", "#/texts/181", "#/texts/182", "#/texts/183"], "page_nos": [], "uuid": "50297ee2-15d4-4025-bceb-fd06b2257767"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 2, "source_chunk_idxs": [3], "num_tokens": 439, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n1 Introduction\nAlzheimer's disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia (\nSperling et al., 2011\n;\nBateman et al., 2012\n;\nDubois et al., 2016\n). Its pathogenesis involves a cascade of interconnected biochemical and cellular changes, including the accumulation of beta-amyloid (A\u03b2) fibrils in extracellular plaques and the hyperphosphorylation of Tau in intracellular tangles. These alterations lead to neuroinflammation, synaptic dysfunction, neuronal degeneration, and ultimately to cognitive and functional decline (\nDe Strooper and Karran, 2016\n). Although genetics plays a significant role (\nSims et al., 2020\n), the precise causes and sequence of these pathological events are not yet completely understood, which can potentially explain the recurring therapeutic failures in AD research. Since treatments may be most effective in the early stages of the disease, it is crucial to identify AD in presymptomatic individuals and those experiencing cognitive decline before reaching the clinically defined MCI or dementia.\nIn the hippocampus, prefrontal cortex, and other areas of the brain that are susceptible to AD pathology, 5-HT2A receptors are highly present (\nBryson et al., 2017\n). Psychedelic drugs, including d-lysergic acid diethylamide (LSD), psilocybin, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and DMT are potent serotonergic agonists with affinity to 5-hydroxytryptamine receptors (5-HTRs) (\nNichols, 2016\n). Recent advances in psychedelic research underscore the numerous connections between these compounds and cognitive/affective alterations observed in older adults (\nAday et al., 2020\n), making them appealing therapeutic candidates for AD.", "doc_items_refs": ["#/texts/185", "#/texts/186", "#/texts/187", "#/texts/188", "#/texts/189", "#/texts/190", "#/texts/191", "#/texts/192", "#/texts/193", "#/texts/194", "#/texts/195", "#/texts/196", "#/texts/197", "#/texts/198", "#/texts/199", "#/texts/200", "#/texts/201", "#/texts/202"], "page_nos": [], "uuid": "a4c31452-1376-45d0-8ae5-1163789e838d"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 3, "source_chunk_idxs": [4], "num_tokens": 278, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n1 Introduction\nStudies in rodents suggest that psychedelics support neurogenesis, neuroplasticity, and neuronal maturation by enhancing the development of neurites, dendritic spines, and synapses in neural progenitor cells, particularly where 5-HT2A receptors are highly expressed (\nLima da Cruz et al., 2018\n;\nMorales-Garcia et al., 2020\n;\nLy et al., 2018\n). These studies have revealed many cellular and molecular mechanisms of these drugs; however, expanding these findings to a human-relevant model is critical for evaluating the therapeutic potential of psychedelics.\nGiven the many differences between human and rodent brains (\nXu et al., 2022\n), it has been challenging to model human brain physiology (particularly that of the hippocampus) in the laboratory. Laboratory-synthesized, human-derived 3D brain organoids represent an\nin vitro\nsystem that effectively models many aspects of the molecular architecture of the human brain (\nChen et al., 2019\n;\nPorci'uncula et al., 2021\n). In this mini review we will briefly summarize the existing literature using cerebral organoids to study the molecular and metabolic alterations caused by various psychedelic compounds, focusing on their potential therapeutic applications for AD.", "doc_items_refs": ["#/texts/203", "#/texts/204", "#/texts/205", "#/texts/206", "#/texts/207", "#/texts/208", "#/texts/209", "#/texts/210", "#/texts/211", "#/texts/212", "#/texts/213", "#/texts/214", "#/texts/215", "#/texts/216", "#/texts/217", "#/texts/218"], "page_nos": [], "uuid": "c8738803-2d24-47ba-bcb6-e5bd14de0013"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 4, "source_chunk_idxs": [5], "num_tokens": 484, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n2 5-MeO-DMT effects\n5-MeO-DMT is a short-acting psychedelic tryptamine that acts as a serotonin receptor agonist with affinity for other receptors, as well as serotonin and norepinephrine transporters (\nErmakova et al., 2022\n).\n5-MeO-DMT has been shown to induce anti-inflammatory pathways and other proteomic alterations in 45-day old human embryonic stem cell-derived cerebral organoids. Following exposure to 5-MeO-DMT for 24-h, shot-gun mass spectrometry (MS) revealed widespread changes in protein expression within toll-like receptor- and Gq-coupled receptor-mediated signaling cascades, ultimately leading to downregulation of transcriptional regulators of inflammatory cytokines, NFAT and NF-\n\u03ba\u03b2\n(\nDakic et al., 2017\n). Other downregulated proteins included srGAP, which is critical for the processes underpinning synaptic plasticity and higher cognitive functions (\nDakic et al., 2017\n;\nNguyen Thi Thanh et al., 2018\n), and mGluR5, which contributes to the rewarding effects of various drugs of abuse; thus, supporting the hypothesis that psychedelics carry a low risk of addiction (\nJohnson et al., 2018\n).\n5-MeO-DMT treatment upregulated the expression of NMDAR, CaMK2, and CREB-signaling molecules involved in long-term potentiation, learning, and memory (\nDakic et al., 2017\n;\nCaya-Bissonnette and B'eique, 2024\n). 5-MeO-DMT significantly increased EFNB2, EPHB, intersectin, ELMO1, CDC42, RAC1, and integrins, which promote dendritic spine development. Finally, 5-MeO-DMT was shown to suppress cell death-related pathways upon activation of\n\u03c3\n1-RS, which induces neuroprotection by modulating intracellular calcium levels and inhibiting the expression of pro-apoptotic genes (\nFigure 1\n) (\nMueller et al., 2013\n).\nFigure 1", "doc_items_refs": ["#/texts/220", "#/texts/221", "#/texts/222", "#/texts/223", "#/texts/224", "#/texts/225", "#/texts/226", "#/texts/227", "#/texts/228", "#/texts/229", "#/texts/230", "#/texts/231", "#/texts/232", "#/texts/233", "#/texts/234", "#/texts/235", "#/texts/236", "#/texts/237", "#/texts/238", "#/texts/239", "#/texts/240", "#/texts/241", "#/texts/242", "#/texts/243", "#/texts/244", "#/texts/245"], "page_nos": [], "uuid": "b9c06b2e-bb95-457c-ba62-c9a050bca502"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 5, "source_chunk_idxs": [6, 7], "num_tokens": 498, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n2 5-MeO-DMT effects\nFigure 1\n. An overview of the state of the current literature evaluating the effects of psychedelic compounds in human cell-derived 3D brain organoids. Presently, only proteomics studies evaluating the effects of d-lysergic acid diethylamide (LSD) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) have been applied to cerebral organoid models.\n\nPsychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n3 LSD effects\nLSD is another psychedelic that predominantly exerts its effects through 5-HT2A receptor antagonism, but also binds to dopaminergic, adrenergic, and other serotonergic receptors (\nDe Gregorio et al., 2021\n). Furthermore, LSD allosterically binds tropomyosin receptor kinase B (TrkB), promoting its interaction with brain-derived neurotrophic factor (BDNF); a key molecule that mediates plastic changes underlying learning and memory (\nFigure 1\n) (\nMoliner et al., 2023\n).\nThe impact of LSD on neural plasticity-related pathways has been evaluated using 45-day-old human-induced pluripotent stem cell (hiPSC)-derived cerebral organoids (\nOrnelas et al., 2022\n). After treatment with 10 nM LSD for 24-h, liquid-chromatography (LC)-MS revealed proteomic alterations involved in common cellular processes including DNA replication, mTOR signaling cascades, and dopamine neurotransmitter release cycle. Specifically, mTOR was significantly upregulated, which may promote psychedelic-induced structural plasticity in the prefrontal cortex (\nLy et al., 2018\n). Other affected pathways reflect neuroplasticity and synaptic reorganization processes, particularly axon guidance, synaptic vesicle cycle, and long-term depression (\nOrnelas et al., 2022\n). In fact, there is evidence that neuronal plasticity is stimulated by LSD through both 5-HT2A and mTOR signaling (\nLy et al., 2018\n).", "doc_items_refs": ["#/texts/246", "#/texts/247", "#/texts/249", "#/texts/250", "#/texts/251", "#/texts/252", "#/texts/253", "#/texts/254", "#/texts/255", "#/texts/256", "#/texts/257", "#/texts/258", "#/texts/259", "#/texts/260", "#/texts/261", "#/texts/262", "#/texts/263", "#/texts/264"], "page_nos": [], "uuid": "322e9652-ad8c-4844-8abc-9254a0afcf7e"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 6, "source_chunk_idxs": [8], "num_tokens": 259, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n3 LSD effects\nIn a subsequent study (\nCosta et al., 2024\n), hiPSC-derived 45-day old human cortical organoids were then exposed to 100 nM LSD for 24 h. LC/MS-MS-based shotgun proteomic analysis revealed a significant shift in the abundance of multiple proteins that modify processes involved in proteostasis, energy metabolism, and neuroplasticity. Most proteostasis proteins were downregulated, possibly prolonging the lifespan of synaptic proteins by slowing turnover rates, although it is unclear whether LSD regulates proteostasis directly or through indirect homeostatic effects. In addition, LSD altered the abundance of proteins associated with glycolysis, the TCA cycle and oxidative phosphorylation, and also increased lactate production, implying that psychedelics could trigger metabolic alterations to meet the high demands of neuroplasticity (\nWatts et al., 2018\n). LSD exposure led to upregulation of synaptic vesicle fusion proteins, suggesting an effect on neuroplasticity and neurotransmitter release.", "doc_items_refs": ["#/texts/265", "#/texts/266", "#/texts/267", "#/texts/268", "#/texts/269"], "page_nos": [], "uuid": "af3ff9d7-6c3b-4250-b3cc-9f103e94157c"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 7, "source_chunk_idxs": [9], "num_tokens": 337, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n4 Discussion\nPreliminary research has highlighted the antidepressant, anxiolytic, and anti-addictive features of classic psychedelics (\nWatts et al., 2018\n). Furthermore, preclinical and neuroimaging studies point to a variety of biological mechanisms of action of psychedelics, including structural and functional enhancement of neuroplasticity (\nLima da Cruz et al., 2018\n;\nLy et al., 2018\n), anti-inflammatory properties (\nFlanagan and Nichols, 2018\n), shifts in critical signaling pathways (i.e., BDNF) (\nLy et al., 2018\n;\nHutten et al., 2020\n), and modifications of functional neural connectivity (\nCarhart-Harris et al., 2017\n;\nBarrett et al., 2020\n;\nPreller et al., 2020\n). The key pathophysiological processes of AD include decreased functional brain activity and connectivity (\nDennis and Thompson, 2014\n), reduced serotonergic neurotransmission (\nSmith et al., 2017\n;\nMecca, 2019\n) associated with neuropsychiatric symptoms (\nButzlaff and Ponimaskin, 2016\n;\nChakraborty et al., 2019\n), neuroinflammation, (\nKinney et al., 2018\n) and alteration of key signaling pathways (i.e., BDNF) (\nPeng et al., 2005\n;\nTanila, 2017\n). Therefore, for many patients with AD, classic psychedelics may offer therapeutic advantages that merit further investigation.", "doc_items_refs": ["#/texts/271", "#/texts/272", "#/texts/273", "#/texts/274", "#/texts/275", "#/texts/276", "#/texts/277", "#/texts/278", "#/texts/279", "#/texts/280", "#/texts/281", "#/texts/282", "#/texts/283", "#/texts/284", "#/texts/285", "#/texts/286", "#/texts/287", "#/texts/288", "#/texts/289", "#/texts/290", "#/texts/291", "#/texts/292", "#/texts/293", "#/texts/294", "#/texts/295", "#/texts/296", "#/texts/297", "#/texts/298", "#/texts/299", "#/texts/300", "#/texts/301", "#/texts/302", "#/texts/303", "#/texts/304", "#/texts/305"], "page_nos": [], "uuid": "e12f33e2-73fb-469c-a653-8353f39ab2e4"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 8, "source_chunk_idxs": [10], "num_tokens": 379, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n4 Discussion\nAlthough two-dimensional (2D) iPSC-derived neuronal cultures are valuable tools to simulate cellular responses, only one study has focused on the neuroprotective impact of the endogenous hallucinogen N,N-dimethyltryptamine (DMT) on human cortical neurons derived from iPSCs, monocyte-derived macrophages, and dendritic cells (\nSzabo et al., 2016\n). Studies investigating the effects of psychedelics in iPSC-derived neurons are exceedingly rare and, to our knowledge, have not yet been conducted in AD patient-derived models. Furthermore, we are not aware of any data that exist from post-mortem AD brain tissue studies. In light of these gaps, iPSC-derived organoids offer a valuable, sophisticated system that closely mimics the spatial architecture of the human brain and incorporates complex cell-to-cell interactions, which may influence drug responses (\nSalerno and Rehen, 2024\n).\nHuman brain organoids provide a unique\nin vitro\nimitation of physiologically relevant complex functions and processes of the human brain (\nLogan et al., 2019\n;\nWhiteley et al., 2022\n), and thus provide valuable data connecting preclinical and clinical studies. Importantly, organoids can be grown using patient-derived iPSCs to serve as tools for precision medicine approaches. Given the highly psychoactive properties of psychedelic substances and the heterogeneous neurobehavioral reactions they evoke (\nMoujaes et al., 2023\n), patient-derived organoids can be used to evaluate personalized treatment strategies that achieve optimal efficacy with minimal adverse effects (\nPark and Mook-Jung, 2022\n).", "doc_items_refs": ["#/texts/306", "#/texts/307", "#/texts/308", "#/texts/309", "#/texts/310", "#/texts/311", "#/texts/312", "#/texts/313", "#/texts/314", "#/texts/315", "#/texts/316", "#/texts/317", "#/texts/318", "#/texts/319", "#/texts/320", "#/texts/321"], "page_nos": [], "uuid": "6c9a519c-6770-42c0-8e27-7081d424ddb7"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 9, "source_chunk_idxs": [11], "num_tokens": 497, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n4 Discussion\nConsidering that serotonergic degeneration is observed early in the course of AD (\nSmith et al., 2023\n) and that psychedelic compounds mediate their effects primarily through the 5-HT2A receptor, hindbrain serotonergic organoids could offer a unique platform to investigate how psychedelics influence serotonergic pathways in the context of AD pathology (\nValiulahi et al., 2021\n;\nZivko et al., 2024\n). The methodological framework developed for studying the response of serotonergic hindbrain organoids to escitalopram (\nZivko et al., 2024\n), a selective serotonin reuptake inhibitor (SSRI), suggests that this platform can be used to explore the potential of psychedelics to treat AD.\nThere is growing evidence that late-life depressive symptoms are associated with an increased risk of incident dementia, a concept that has been codified into the construct of 'mild behavioral impairment' (\nCreese and Ismail, 2022\n). In the data set of the National Alzheimer's Coordinating Center, the majority of participants who progressed from normal to impaired cognition presented behavioral symptoms prior to cognitive changes (\nWise et al., 2019\n). Thus, the mechanisms underlying late-life depression may also be the basis for neurodegenerative disease. Many of the mechanisms identified by the aforementioned organoid studies are common to depression and AD, including decreased serotonergic innervation, neuroinflammation, and disruptions in crucial signaling pathways, including BDNF (\nMendes-Silva et al., 2016\n;\nLinnemann and Lang, 2020\n;\nBajaj and Mahesh, 2024\n). Clinical trials have shown that a single dose of a psychedelic can induce lasting physiological changes across multiple neural pathways without the need for sustained or repeated exposure to maintain these effects (\nKnudsen, 2023\n). This is analogous to the observation that a single dose of psilocybin was effective in treating major depression both in the short term (3 weeks) (\nGoodwin et al., 2022\n) and in a long-term open-label follow-up over 52 weeks (\nGoodwin et al., 2025\n), suggesting that a single psychedelic dose can induce long-term alterations in the human brain.", "doc_items_refs": ["#/texts/322", "#/texts/323", "#/texts/324", "#/texts/325", "#/texts/326", "#/texts/327", "#/texts/328", "#/texts/329", "#/texts/330", "#/texts/331", "#/texts/332", "#/texts/333", "#/texts/334", "#/texts/335", "#/texts/336", "#/texts/337", "#/texts/338", "#/texts/339", "#/texts/340", "#/texts/341", "#/texts/342", "#/texts/343", "#/texts/344", "#/texts/345", "#/texts/346", "#/texts/347"], "page_nos": [], "uuid": "e8434f7b-e0c0-43b7-a8d4-749dd17ae4f7"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 10, "source_chunk_idxs": [12], "num_tokens": 252, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n4 Discussion\nPsilocybin is another psychedelic that is being evaluated as a treatment for several neurological disorders (\nCarhart-Harris et al., 2021\n;\nSchindler et al., 2021\n;\nDaws et al., 2022\n). Although its application as a medical intervention for AD has been understudied, it has been recognized as a breakthrough therapy for major depressive disorder (\nRaison et al., 2023\n;\nZheng et al., 2024\n). Considering the potential of psilocybin to induce neurogenesis, synaptogenesis, and synaptic plasticity (\nJefsen et al., 2020\n;\nShao et al., 2021\n;\nRaval et al., 2021\n), it may represent a strong candidate for trials in human brain organoids, with the aim of exploring its potential therapeutic benefit for AD. Furthermore, depression and anxiety are prominent symptoms of AD and can accelerate the progression of the disease (\nMa, 2020\n;\nAg\u00fcera-Ortiz et al., 2021\n). Therefore, psilocybin may alleviate affective symptoms and even delay the course of the disease.", "doc_items_refs": ["#/texts/348", "#/texts/349", "#/texts/350", "#/texts/351", "#/texts/352", "#/texts/353", "#/texts/354", "#/texts/355", "#/texts/356", "#/texts/357", "#/texts/358", "#/texts/359", "#/texts/360", "#/texts/361", "#/texts/362", "#/texts/363", "#/texts/364", "#/texts/365", "#/texts/366", "#/texts/367", "#/texts/368"], "page_nos": [], "uuid": "f82be7e2-4b6b-4d6e-a371-f8fdb40c0768"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 11, "source_chunk_idxs": [13], "num_tokens": 379, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\n4 Discussion\nDespite a growing body of evidence supporting the therapeutic potential of psychedelics across various medical conditions, their use remains controversial due to lingering stigma around historical misuse. Notably, several perceived risks, such as addiction and neurotoxicity, have been refuted by recent research (\nSchlag et al., 2022\n). However, other potential risks, such as the exacerbation of delusions or hallucinations following high-dose psychedelic administration, remain a concern, particularly in individuals with advanced AD (\nScarmeas et al., 2005\n). As a result, research into the therapeutic potential of psychedelics is increasingly focused on the earliest stages of the disease (\nGarcia-Romeu et al., 2022\n). In this context, a rational approach may involve eliminating the hallucinogenic effects of these compounds while preserving their therapeutic benefits, potentially minimizing adverse side effects (\nYin and Gao, 2023\n). Moreover, to support this effort, advanced model systems such as organoids could offer the potential to understand the mechanisms underlying the heterogeneity of the clinical response, guiding the development of more targeted therapeutic strategies (\nZhou et al., 2023\n;\nGiorgi et al., 2024\n;\nSmirnova and Hartung, 2024\n).\nAltogether, strong evidence suggests that psychedelic drugs mediate plastogenic and anti-inflammatory processes in brain regions involved in AD pathology, which makes them promising cognitive enhancers and prospective therapeutic candidates. Given the high value of human cerebral organoids as tools for conducting preclinical research in a human-relevant environment, more studies in this direction are required to gain a comprehensive understanding of the mechanisms behind the neurorestorative impact of these compounds on the human brain.", "doc_items_refs": ["#/texts/369", "#/texts/370", "#/texts/371", "#/texts/372", "#/texts/373", "#/texts/374", "#/texts/375", "#/texts/376", "#/texts/377", "#/texts/378", "#/texts/379", "#/texts/380", "#/texts/381", "#/texts/382", "#/texts/383", "#/texts/384"], "page_nos": [], "uuid": "77f46a62-0530-4e96-b423-1935b12362a2"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 12, "source_chunk_idxs": [14, 15, 16, 17], "num_tokens": 399, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nAuthor contributions\nXA: Writing - original draft, Writing - review &amp; editing. RB: Visualization, Writing - review &amp; editing. PR: Writing - review &amp; editing. VM: Writing - original draft, Writing - review &amp; editing.\n\nPsychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nFunding\nThe author(s) declare that financial support was received for the research and/or publication of this article. VM was supported from The Richman Family Precision Medicine Center of Excellence in Alzheimer's disease at Johns Hopkins and the NIH RF1AG083801 grant. RB was supported by The National Institutes of Health Research (T32AG058527).\n\nPsychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nAcknowledgments\nThe authors would also like to acknowledge support by The Richman Family Precision Medicine Center of Excellence in Alzheimer's disease at Johns Hopkins. Figures were created using\nBioRender.com\n.\n\nPsychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nConflict of interest\nRosenberg received research grants from the National Institutes of Aging, Alzheimer's Clinical Trials Consortium, Richman Family Precision Medicine Center of Excellence on Alzheimer's Disease, Eisai, Functional Neuromodulation, and Lilly; honoraria from Lilly, GLG, Leerink, Medalink, Novo Nordisk, Noble Insights, TwoLabs, Otsuka, MedaCorp, ExpertConnect, HMP Global, Worldwide Clinical Trials, Medscape, and Neurology Week.\nThe remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", "doc_items_refs": ["#/texts/386", "#/texts/388", "#/texts/390", "#/texts/391", "#/texts/392", "#/texts/394", "#/texts/395"], "page_nos": [], "uuid": "3251513a-734e-4963-bfc8-6071fd2941dd"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 13, "source_chunk_idxs": [18, 19], "num_tokens": 130, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nGenerative AI statement\nThe authors declare that no Gen AI was used in the creation of this manuscript.\n\nPsychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nPublisher's note\nAll claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", "doc_items_refs": ["#/texts/397", "#/texts/399"], "page_nos": [], "uuid": "75f07559-350a-4295-ac3c-7c5f59128852"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 14, "source_chunk_idxs": [20], "num_tokens": 434, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nAday, J. S., Bloesch, E. K., and Davoli, C. C. (2020). Can psychedelic drugs attenuate age-related changes in cognition and affect?\nJ. Cogn. Enhanc.\n4, 219-227. doi: 10.1007/s41465-019-00151-6\nCrossref Full Text\n|\nGoogle Scholar\nAg\u00fcera-Ortiz, R., Garc'\u0131a-Ramos, F. J., Grandas P'erez, J., L'opez-\u00c1lvarez, J. M., Montes Rodr'\u0131guez, F. J., Olazar'an Rodr'\u0131guez, J., et al. (2021). Depression in Alzheimer's disease: a delphi consensus on etiology, risk factors, and clinical management.\nFront. Psych.\n12:638651. doi: 10.3389/fpsyt.2021.638651\nCrossref Full Text\n|\nGoogle Scholar\nBajaj, S., and Mahesh, R. (2024). Converged avenues: depression and Alzheimer's disease-shared pathophysiology and novel therapeutics.\nMol. Biol. Rep.\n51:225. doi: 10.1007/s11033-023-09170-1\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nBarrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., and Griffiths, R. R. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin.\nSci. Rep.\n10:2214. doi: 10.1038/s41598-020-59282-y\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/401", "#/texts/402", "#/texts/403", "#/texts/404", "#/texts/405", "#/texts/406", "#/texts/407", "#/texts/408", "#/texts/409", "#/texts/410", "#/texts/411", "#/texts/412", "#/texts/413", "#/texts/414", "#/texts/415", "#/texts/416", "#/texts/417", "#/texts/418", "#/texts/419", "#/texts/420", "#/texts/421", "#/texts/422", "#/texts/423", "#/texts/424", "#/texts/425", "#/texts/426", "#/texts/427", "#/texts/428"], "page_nos": [], "uuid": "609e233b-4543-4485-8c5e-52caa7dfa17e"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 15, "source_chunk_idxs": [21], "num_tokens": 501, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nBateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease.\nN. Engl. J. Med.\n367, 795-804. doi: 10.1056/NEJMoa1202753\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nBryson, O., Carter, T., Norman, R., and Kanaan, R. (2017). 5-HT2A agonists: a novel therapy for functional neurological disorders?\nInt. J. Neuropsychopharmacol.\n20, 422-427. doi: 10.1093/ijnp/pyx011\nCrossref Full Text\n|\nGoogle Scholar\nButzlaff, M., and Ponimaskin, E. (2016). The role of serotonin receptors in Alzheimer's disease.\nOper. Med. Physiol.\n2:18. doi: 10.20388/omp2016.001.0018\nCrossref Full Text\n|\nGoogle Scholar\nCarhart-Harris, R. L., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., et al. (2021). Trial of psilocybin versus escitalopram for depression.\nN. Engl. J. Med.\n384, 1402-1411. doi: 10.1056/NEJMoa2032994\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nCarhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., et al. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.\nSci. Rep.\n7:13187. doi: 10.1038/s41598-017-13282-7", "doc_items_refs": ["#/texts/429", "#/texts/430", "#/texts/431", "#/texts/432", "#/texts/433", "#/texts/434", "#/texts/435", "#/texts/436", "#/texts/437", "#/texts/438", "#/texts/439", "#/texts/440", "#/texts/441", "#/texts/442", "#/texts/443", "#/texts/444", "#/texts/445", "#/texts/446", "#/texts/447", "#/texts/448", "#/texts/449", "#/texts/450", "#/texts/451", "#/texts/452", "#/texts/453", "#/texts/454", "#/texts/455", "#/texts/456", "#/texts/457", "#/texts/458", "#/texts/459"], "page_nos": [], "uuid": "aeb20f1b-22f3-4103-afb4-781c3b40abe4"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 16, "source_chunk_idxs": [22], "num_tokens": 490, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nCaya-Bissonnette, L., and B'eique, J. C. (2024). Half a century legacy of long-term potentiation.\nCurr. Biol.\n34, R640-R662. doi: 10.1016/j.cub.2024.05.008\nCrossref Full Text\n|\nGoogle Scholar\nChakraborty, S., Lennon, J. C., Malkaram, S. A., Zeng, Y., Fisher, D. W., and Dong, H. (2019). Serotonergic system, cognition, and BPSD in Alzheimer's disease.\nNeurosci. Lett.\n704, 36-44. doi: 10.1016/j.neulet.2019.03.050\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nChen, H. I., Song, H., and Ming, G.-l. (2019). Applications of human brain organoids to clinical problems.\nDev. Dyn.\n248, 53-64. doi: 10.1002/dvdy.24662\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nCosta, M. N., Goto-Silva, L., Nascimento, J. M., Domith, I., Karmirian, K., Feilding, A., et al. (2024). LSD modulates proteins involved in cell proteostasis, energy metabolism and neuroplasticity in human cerebral organoids.\nACS Omega\n9, 36553-36568. doi: 10.1021/acsomega.4c04712\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nCreese, B., and Ismail, Z. (2022). Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer's disease.\nAlzheimers Res. Ther.\n14:2. doi: 10.1186/s13195-021-00949-7\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/460", "#/texts/461", "#/texts/462", "#/texts/463", "#/texts/464", "#/texts/465", "#/texts/466", "#/texts/467", "#/texts/468", "#/texts/469", "#/texts/470", "#/texts/471", "#/texts/472", "#/texts/473", "#/texts/474", "#/texts/475", "#/texts/476", "#/texts/477", "#/texts/478", "#/texts/479", "#/texts/480", "#/texts/481", "#/texts/482", "#/texts/483", "#/texts/484", "#/texts/485", "#/texts/486", "#/texts/487", "#/texts/488", "#/texts/489", "#/texts/490", "#/texts/491", "#/texts/492", "#/texts/493", "#/texts/494", "#/texts/495", "#/texts/496", "#/texts/497", "#/texts/498", "#/texts/499", "#/texts/500", "#/texts/501", "#/texts/502"], "page_nos": [], "uuid": "d692bfc3-3345-4995-963f-feb1c85e6fb6"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 17, "source_chunk_idxs": [23], "num_tokens": 511, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nDakic, V., Nascimento, J. M., Sartore, R. C., Maciel, R. M., de Araujo, D. B., Ribeiro, S., et al. (2017). Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT.\nSci. Rep.\n7:12863. doi: 10.1038/s41598-017-12779-5\nCrossref Full Text\n|\nGoogle Scholar\nDaws, R. E., Timmermann, C., Giribaldi, B., Sexton, J. D., Wall, M. B., Erritzoe, D., et al. (2022). Increased global integration in the brain after psilocybin therapy for depression.\nNat. Med.\n28, 844-851. doi: 10.1038/s41591-022-01744-z\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nDe Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., et al. (2021). Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine.\nJ. Neurosci.\n41, 891-900. doi: 10.1523/JNEUROSCI.1659-20.2020\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nDe Strooper, B., and Karran, E. (2016). The cellular phase of Alzheimer's disease.\nCell\n164, 603-615. doi: 10.1016/j.cell.2015.12.056\nCrossref Full Text\n|\nGoogle Scholar\nDennis, E. L., and Thompson, P. M. (2014). Functional brain connectivity using fMRI in aging and Alzheimer's disease.\nNeuropsychol. Rev.\n24, 49-62. doi: 10.1007/s11065-014-9249-6\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/503", "#/texts/504", "#/texts/505", "#/texts/506", "#/texts/507", "#/texts/508", "#/texts/509", "#/texts/510", "#/texts/511", "#/texts/512", "#/texts/513", "#/texts/514", "#/texts/515", "#/texts/516", "#/texts/517", "#/texts/518", "#/texts/519", "#/texts/520", "#/texts/521", "#/texts/522", "#/texts/523", "#/texts/524", "#/texts/525", "#/texts/526", "#/texts/527", "#/texts/528", "#/texts/529", "#/texts/530", "#/texts/531", "#/texts/532", "#/texts/533", "#/texts/534", "#/texts/535", "#/texts/536"], "page_nos": [], "uuid": "25db29a8-add4-4715-a1dd-75a1f526f9e0"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 18, "source_chunk_idxs": [24], "num_tokens": 474, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nDubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., et al. (2016). Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria.\nAlzheimers Dement.\n12, 292-323. doi: 10.1016/j.jalz.2016.02.002\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nErmakova, A. O., Dunbar, F., Rucker, J., and Johnson, M. W. (2022). A narrative synthesis of research with 5-MeO-DMT.\nJ. Psychopharmacol.\n36, 273-294. doi: 10.1177/02698811211050543\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nFlanagan, T. W., and Nichols, C. D. (2018). Psychedelics as anti-inflammatory agents.\nInt. Rev. Psychiatry\n30, 363-375. doi: 10.1080/09540261.2018.1481827\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nGarcia-Romeu, S., Darcy, S., Jackson, H., White, T., and Rosenberg, P. (2022). Psychedelics as novel therapeutics in Alzheimer's disease: rationale and potential mechanisms.\nCurr. Top. Behav. Neurosci.\n56, 287-317. doi: 10.1007/78542021267\nCrossref Full Text\n|\nGoogle Scholar\nGiorgi, C., Lombardozzi, G., Ammannito, F., Scenna, M. S., Maceroni, E., Quintiliani, M., et al. (2024). Brain organoids: a game-changer for drug testing.\nPharmaceutics\n16:443. doi: 10.3390/pharmaceutics16040443\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/537", "#/texts/538", "#/texts/539", "#/texts/540", "#/texts/541", "#/texts/542", "#/texts/543", "#/texts/544", "#/texts/545", "#/texts/546", "#/texts/547", "#/texts/548", "#/texts/549", "#/texts/550", "#/texts/551", "#/texts/552", "#/texts/553", "#/texts/554", "#/texts/555", "#/texts/556", "#/texts/557", "#/texts/558", "#/texts/559", "#/texts/560", "#/texts/561", "#/texts/562", "#/texts/563", "#/texts/564", "#/texts/565", "#/texts/566", "#/texts/567", "#/texts/568", "#/texts/569", "#/texts/570", "#/texts/571", "#/texts/572"], "page_nos": [], "uuid": "883c189d-8f8d-46a7-9d67-87ec1ac0cbce"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 19, "source_chunk_idxs": [25], "num_tokens": 468, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nGoodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression.\nN. Engl. J. Med.\n387, 1637-1648. doi: 10.1056/NEJMoa2206443\nCrossref Full Text\n|\nGoogle Scholar\nGoodwin, G. M., Aaronson, S. T., Alvarez, O., Carhart-Harris, R., Chai-Rees, J., Croal, M., et al. (2025). The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.\nJ. Affect. Disord.\n372, 523-532. doi: 10.1016/j.jad.2024.12.061\nCrossref Full Text\n|\nGoogle Scholar\nHutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., et al. (2020). Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers.\nACS Pharmacol. Transl. Sci.\n4, 461-466. doi: 10.1021/acsptsci.0c00099\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nJefsen, O. H., Elfving, B., Wegener, G., and M\u00fcller, H. K. (2020). Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin.\nJ. Psychopharmacol.\n35, 483-493. doi: 10.1177/0269881120959614\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/573", "#/texts/574", "#/texts/575", "#/texts/576", "#/texts/577", "#/texts/578", "#/texts/579", "#/texts/580", "#/texts/581", "#/texts/582", "#/texts/583", "#/texts/584", "#/texts/585", "#/texts/586", "#/texts/587", "#/texts/588", "#/texts/589", "#/texts/590", "#/texts/591", "#/texts/592", "#/texts/593", "#/texts/594", "#/texts/595", "#/texts/596", "#/texts/597", "#/texts/598", "#/texts/599", "#/texts/600"], "page_nos": [], "uuid": "50397940-18f4-4c99-a2fc-1db0e7386e6d"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 20, "source_chunk_idxs": [26], "num_tokens": 480, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nJohnson, M. W., Griffiths, R. R., Hendricks, P. S., and Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act.\nNeuropharmacology\n142, 143-166. doi: 10.1016/j.neuropharm.2018.05.012\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nKinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., and Lamb, B. T. (2018). Inflammation as a central mechanism in Alzheimer's disease.\nAlzheimers Dement (N Y)\n4, 575-590. doi: 10.1016/j.trci.2018.06.014\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nKnudsen, G. M. (2023). Sustained effects of single doses of classical psychedelics in humans.\nNeuropsychopharmacology\n48, 145-150. doi: 10.1038/s41386-022-01361-x\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nLima da Cruz, R. V., Moulin, T. C., Petiz, L. L., and Le\u00e3o, R. N. (2018). A single dose of 5-MeO-DMT stimulates cell proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus.\nFront. Mol. Neurosci.\n11:312. doi: 10.3389/fnmol.2018.00312\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nLinnemann, C., and Lang, U. E. (2020). Pathways connecting late-life depression and dementia.\nFront. Pharmacol.\n11:279. doi: 10.3389/fphar.2020.00279\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/601", "#/texts/602", "#/texts/603", "#/texts/604", "#/texts/605", "#/texts/606", "#/texts/607", "#/texts/608", "#/texts/609", "#/texts/610", "#/texts/611", "#/texts/612", "#/texts/613", "#/texts/614", "#/texts/615", "#/texts/616", "#/texts/617", "#/texts/618", "#/texts/619", "#/texts/620", "#/texts/621", "#/texts/622", "#/texts/623", "#/texts/624", "#/texts/625", "#/texts/626", "#/texts/627", "#/texts/628", "#/texts/629", "#/texts/630", "#/texts/631", "#/texts/632", "#/texts/633", "#/texts/634", "#/texts/635", "#/texts/636", "#/texts/637", "#/texts/638", "#/texts/639", "#/texts/640"], "page_nos": [], "uuid": "7bf988e8-4473-482b-aba2-22cd3646aa36"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 21, "source_chunk_idxs": [27], "num_tokens": 504, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nLogan, S., Arzua, T., Canfield, S. G., Seminary, E. R., Sison, S. L., Ebert, A. D., et al. (2019). Studying human neurological disorders using induced pluripotent stem cells: from 2D monolayer to 3D organoid and blood brain barrier models.\nCompr. Physiol.\n9, 565-611. doi: 10.1002/cphy.c180025\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nLy, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., et al. (2018). Psychedelics promote structural and functional neural plasticity.\nCell Rep.\n23, 3170-3182. doi: 10.1016/j.celrep.2018.05.022\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nMa, L. (2020). Depression, anxiety, and apathy in mild cognitive impairment: current perspectives.\nFront. Aging Neurosci.\n12:9. doi: 10.3389/fnagi.2020.00009\nCrossref Full Text\n|\nGoogle Scholar\nMecca, A. P. (2019). AD molecular: molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systems.\nProg Mol Biol Transl Sci\n165, 139-165. doi: 10.1016/bs.pmbts.2019.04.003\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nMendes-Silva, P., Pereira, K. S., Tolentino-Araujo, G. T., Nicolau, E. d. S., Silva-Ferreira, C. M., Teixeira, A. L.'u., et al. (2016). Shared biologic pathways between Alzheimer disease and major depression: a systematic review of MicroRNA expression studies.\nAm. J. Geriatr. Psychiatry\n24, 903-912. doi: 10.1016/j.jagp.2016.07.017\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/641", "#/texts/642", "#/texts/643", "#/texts/644", "#/texts/645", "#/texts/646", "#/texts/647", "#/texts/648", "#/texts/649", "#/texts/650", "#/texts/651", "#/texts/652", "#/texts/653", "#/texts/654", "#/texts/655", "#/texts/656", "#/texts/657", "#/texts/658", "#/texts/659", "#/texts/660", "#/texts/661", "#/texts/662", "#/texts/663", "#/texts/664", "#/texts/665", "#/texts/666", "#/texts/667", "#/texts/668", "#/texts/669", "#/texts/670", "#/texts/671", "#/texts/672", "#/texts/673", "#/texts/674", "#/texts/675", "#/texts/676"], "page_nos": [], "uuid": "c7ee3c0a-5ecb-46b1-9bc3-8eebeaaab984"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 22, "source_chunk_idxs": [28], "num_tokens": 511, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nMoliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., et al. (2023). Psychedelics promote plasticity by directly binding to BDNF receptor TrkB.\nNat. Neurosci.\n26, 1032-1041. doi: 10.1038/s41593-023-01316-5\nCrossref Full Text\n|\nGoogle Scholar\nMorales-Garcia, J. A., Calleja-Conde, J., Lopez-Moreno, J. A., Alonso-Gil, S., Sanz-SanCristobal, M., Riba, J., et al. (2020). N,n-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo.\nTransl. Psychiatry\n10:331. doi: 10.1038/s41398-020-01011-0\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nMoujaes, F., Preller, K. H., Ji, J. L., Murray, J. D., Berkovitch, L., Vollenweider, F. X., et al. (2023). Toward mapping neurobehavioral heterogeneity of psychedelic neurobiology in humans.\nBiol. Psychiatry\n93, 1061-1070. doi: 10.1016/j.biopsych.2022.10.021\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nMueller, B. H., Park, Y., Daudt, D. R., Ma, H.-Y., Akopova, I., Stankowska, D. L., et al. (2013). Sigma-1 receptor stimulation attenuates calcium influx through activated L-type voltage gated calcium channels in purified retinal ganglion cells.\nExp. Eye Res.\n107, 21-31. doi: 10.1016/j.exer.2012.11.002\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/677", "#/texts/678", "#/texts/679", "#/texts/680", "#/texts/681", "#/texts/682", "#/texts/683", "#/texts/684", "#/texts/685", "#/texts/686", "#/texts/687", "#/texts/688", "#/texts/689", "#/texts/690", "#/texts/691", "#/texts/692", "#/texts/693", "#/texts/694", "#/texts/695", "#/texts/696", "#/texts/697", "#/texts/698", "#/texts/699", "#/texts/700", "#/texts/701", "#/texts/702", "#/texts/703", "#/texts/704", "#/texts/705", "#/texts/706"], "page_nos": [], "uuid": "b3f800fb-b72d-44b3-b563-1434fea1991f"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 23, "source_chunk_idxs": [29], "num_tokens": 469, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nNguyen Thi Thanh, H., Kutzner, A., and Heese, K. (2018). Brain plasticity, cognitive functions and neural stem cells: a pivotal role for the brain-specific neural master gene SRGAP2-FAM72.\nBiol. Chem.\n399, 55-61. doi: 10.1515/hsz-2017-0190\nCrossref Full Text\n|\nGoogle Scholar\nNichols, D. E. (2016). Psychedelics.\nPharmacol. Rev.\n68, 264-355. doi: 10.1124/pr.115.011478\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nOrnelas, I. M., Cini, F. A., Wie\u00dfner, I., Marcos, E., Ara'ujo, D.'a. B., Goto-Silva, L., et al. (2022). Nootropic effects of LSD: behavioral, molecular and computational evidence.\nExp. Neurol.\n356:114148. doi: 10.1016/j.expneurol.2022.114148\nCrossref Full Text\n|\nGoogle Scholar\nPark, J.-C., and Mook-Jung, I. (2022). Toward brain organoid-based precision medicine in neurodegenerative diseases.\nOrgan\n2:e21. doi: 10.51335/organoid.2022.2.e21\nCrossref Full Text\n|\nGoogle Scholar\nPeng, S., Wuu, J., Mufson, E. J., and Fahnestock, M. (2005). Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease.\nJ. Neurochem.\n93, 1412-1421. doi: 10.1111/j.1471-4159.2005.03135.x\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/707", "#/texts/708", "#/texts/709", "#/texts/710", "#/texts/711", "#/texts/712", "#/texts/713", "#/texts/714", "#/texts/715", "#/texts/716", "#/texts/717", "#/texts/718", "#/texts/719", "#/texts/720", "#/texts/721", "#/texts/722", "#/texts/723", "#/texts/724", "#/texts/725", "#/texts/726", "#/texts/727", "#/texts/728", "#/texts/729", "#/texts/730", "#/texts/731", "#/texts/732", "#/texts/733", "#/texts/734", "#/texts/735", "#/texts/736", "#/texts/737", "#/texts/738", "#/texts/739", "#/texts/740"], "page_nos": [], "uuid": "d0a742ba-7c0d-4f22-9a8d-56da843eccd6"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 24, "source_chunk_idxs": [30], "num_tokens": 511, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nPorci'uncula, L. O., Goto-Silva, L., Ledur, F. F., and Rehen, S. K. (2021). The age of brain organoids: tailoring cell identity and functionality for normal brain development and disease modeling.\nFront. Neurosci.\n15:674563. doi: 10.3389/fnins.2021.674563\nCrossref Full Text\n|\nGoogle Scholar\nPreller, K. H., Duerler, P., Burt, J. B., Ji, J. L., Adkinson, B., St\u00e4mpfli, P., et al. (2020). Psilocybin induces time-dependent changes in global functional connectivity.\nBiol. Psychiatry\n88, 197-207. doi: 10.1016/j.biopsych.2019.12.027\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nRaison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., et al. (2023). Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.\nJAMA\n330, 843-853. doi: 10.1001/jama.2023.14530\nCrossref Full Text\n|\nGoogle Scholar\nRaval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., et al. (2021). A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain.\nInt. J. Mol. Sci.\n22:835. doi: 10.3390/ijms22020835\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nSalerno, J. A., and Rehen, S. (2024). Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro.\niScience\n27:109631. doi: 10.1016/j.isci.2024.109631", "doc_items_refs": ["#/texts/741", "#/texts/742", "#/texts/743", "#/texts/744", "#/texts/745", "#/texts/746", "#/texts/747", "#/texts/748", "#/texts/749", "#/texts/750", "#/texts/751", "#/texts/752", "#/texts/753", "#/texts/754", "#/texts/755", "#/texts/756", "#/texts/757", "#/texts/758", "#/texts/759", "#/texts/760", "#/texts/761", "#/texts/762", "#/texts/763", "#/texts/764", "#/texts/765", "#/texts/766", "#/texts/767", "#/texts/768", "#/texts/769", "#/texts/770", "#/texts/771"], "page_nos": [], "uuid": "ae99d8c3-4aa3-4c4a-9197-b4e6ff574dfe"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 25, "source_chunk_idxs": [31], "num_tokens": 476, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nScarmeas, N., Brandt, J., Albert, M., Hadjigeorgiou, G., Papadimitriou, A., Dubois, B., et al. (2005). Delusions and hallucinations are associated with worse outcome in Alzheimer disease.\nArch. Neurol.\n62, 1601-1608. doi: 10.1001/archneur.62.10.1601\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nSchindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Luddy, C., Flynn, L. T., Lindsey, H., et al. (2021). Exploratory controlled study of the migraine-suppressing effects of psilocybin.\nNeurotherapeutics\n18, 534-543. doi: 10.1007/s13311-020-00962-y\nCrossref Full Text\n|\nGoogle Scholar\nSchlag, A. K., Aday, J., Salam, I., Neill, J. C., and Nutt, D. J. (2022). Adverse effects of psychedelics: from anecdotes and misinformation to systematic science.\nJ. Psychopharmacol.\n36, 258-272. doi: 10.1177/02698811211069100\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nShao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., et al. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo.\nNeuron\n109, 2535-2544.e4. doi: 10.1016/j.neuron.2021.06.008\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/772", "#/texts/773", "#/texts/774", "#/texts/775", "#/texts/776", "#/texts/777", "#/texts/778", "#/texts/779", "#/texts/780", "#/texts/781", "#/texts/782", "#/texts/783", "#/texts/784", "#/texts/785", "#/texts/786", "#/texts/787", "#/texts/788", "#/texts/789", "#/texts/790", "#/texts/791", "#/texts/792", "#/texts/793", "#/texts/794", "#/texts/795", "#/texts/796", "#/texts/797", "#/texts/798", "#/texts/799", "#/texts/800", "#/texts/801", "#/texts/802", "#/texts/803", "#/texts/804", "#/texts/805", "#/texts/806"], "page_nos": [], "uuid": "d2c836dd-2cbb-48cb-a3cc-b90d9101c55c"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 26, "source_chunk_idxs": [32], "num_tokens": 506, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nSims, R., Hill, M., and Williams, J. (2020). The multiplex model of the genetics of Alzheimer's disease.\nNat. Neurosci.\n23, 311-322. doi: 10.1038/s41593-020-0599-5\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nSmirnova, L., and Hartung, T. (2024). The promise and potential of brain organoids.\nAdv. Healthc. Mater.\n13:e2302745. doi: 10.1002/adhm.202302745\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nSmith, G. S., Barrett, F. S., Joo, J. H., Nassery, N., Savonenko, A., Sodums, D. J., et al. (2017). Molecular imaging of serotonin degeneration in mild cognitive impairment.\nNeurobiol. Dis.\n105, 33-41. doi: 10.1016/j.nbd.2017.05.007\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nSmith, G. S., Protas, H., Kuwabara, H., Savonenko, A., Nassery, N., Gould, N. F., et al. (2023). Molecular imaging of the association between serotonin degeneration and beta-amyloid deposition in mild cognitive impairment.\nNeuroImage Clin.\n37:103322. doi: 10.1016/j.nicl.2023.103322\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease.\nAlzheimers Dement.\n7, 280-292. doi: 10.1016/j.jalz.2011.03.003", "doc_items_refs": ["#/texts/807", "#/texts/808", "#/texts/809", "#/texts/810", "#/texts/811", "#/texts/812", "#/texts/813", "#/texts/814", "#/texts/815", "#/texts/816", "#/texts/817", "#/texts/818", "#/texts/819", "#/texts/820", "#/texts/821", "#/texts/822", "#/texts/823", "#/texts/824", "#/texts/825", "#/texts/826", "#/texts/827", "#/texts/828", "#/texts/829", "#/texts/830", "#/texts/831", "#/texts/832", "#/texts/833", "#/texts/834", "#/texts/835", "#/texts/836", "#/texts/837", "#/texts/838", "#/texts/839", "#/texts/840", "#/texts/841"], "page_nos": [], "uuid": "48c92919-ac38-474e-b7df-97f8c468c1b8"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 27, "source_chunk_idxs": [33], "num_tokens": 441, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nSzabo, A., Kovacs, A., Riba, J., Djurovic, S., Rajnavolgyi, E., and Frecska, E. (2016). The endogenous hallucinogen and trace amine N,N-dimethyltryptamine (DMT) displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary iPSC-derived cortical neurons and microglia-like immune cells.\nFront. Neurosci.\n10:423. doi: 10.3389/fnins.2016.00423\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nTanila, H. (2017). The role of BDNF in Alzheimer's disease.\nNeurobiol. Dis.\n97, 114-118. doi: 10.1016/j.nbd.2016.05.008\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nValiulahi, P., Vidyawan, V., Puspita, L., Oh, Y., Juwono, V. B., Sittipo, P., et al. (2021). Generation of caudal-type serotonin neurons and hindbrain-fate organoids from hPSCs.\nStem Cell Rep.\n16, 1938-1952. doi: 10.1016/j.stemcr.2021.06.006\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nWatts, M. E., Pocock, R., and Claudianos, C. (2018). Brain energy and oxygen metabolism: emerging role in normal function and disease.\nFront. Mol. Neurosci.\n11:216. doi: 10.3389/fnmol.2018.00216\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/842", "#/texts/843", "#/texts/844", "#/texts/845", "#/texts/846", "#/texts/847", "#/texts/848", "#/texts/849", "#/texts/850", "#/texts/851", "#/texts/852", "#/texts/853", "#/texts/854", "#/texts/855", "#/texts/856", "#/texts/857", "#/texts/858", "#/texts/859", "#/texts/860", "#/texts/861", "#/texts/862", "#/texts/863", "#/texts/864", "#/texts/865", "#/texts/866", "#/texts/867", "#/texts/868", "#/texts/869", "#/texts/870", "#/texts/871", "#/texts/872", "#/texts/873", "#/texts/874", "#/texts/875", "#/texts/876", "#/texts/877", "#/texts/878"], "page_nos": [], "uuid": "8c939b6f-f8cf-4970-9d4a-d0566b3353bb"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 28, "source_chunk_idxs": [34], "num_tokens": 498, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nWhiteley, J. T., Fernandes, S., Sharma, A., Mendes, A. P. D., Racha, V., Benassi, S. K., et al. (2022). Reaching into the toolbox: stem cell models to study neuropsychiatric disorders.\nStem Cell Rep.\n17, 187-210. doi: 10.1016/j.stemcr.2021.12.015\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nWise, E. A., Rosenberg, P. B., Lyketsos, C. G., and Leoutsakos, J.-M. (2019). Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's coordinating centers volunteers.\nAlzheimers Dement (N Y).\n11, 333-339. doi: 10.1016/j.dadm.2019.02.006\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nXu, N., LaGrow, T. J., Anumba, N., Lee, A., Zhang, X., Yousefi, B., et al. (2022). Functional connectivity of the brain across rodents and humans.\nFront. Neurosci.\n16:816331. doi: 10.3389/fnins.2022.816331\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nYin, Y. N., and Gao, T. M. (2023). Non-hallucinogenic psychedelic analog design: a promising direction for depression treatment.\nNeurosci. Bull.\n39, 170-172. doi: 10.1007/s12264-022-00933-7\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nZheng, S., Ma, R., Yang, Y., and Li, G. (2024). Psilocybin for the treatment of Alzheimer's disease.\nFront. Neurosci.\n18:1420601. doi: 10.3389/fnins.2024.1420601\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar", "doc_items_refs": ["#/texts/879", "#/texts/880", "#/texts/881", "#/texts/882", "#/texts/883", "#/texts/884", "#/texts/885", "#/texts/886", "#/texts/887", "#/texts/888", "#/texts/889", "#/texts/890", "#/texts/891", "#/texts/892", "#/texts/893", "#/texts/894", "#/texts/895", "#/texts/896", "#/texts/897", "#/texts/898", "#/texts/899", "#/texts/900", "#/texts/901", "#/texts/902", "#/texts/903", "#/texts/904", "#/texts/905", "#/texts/906", "#/texts/907", "#/texts/908", "#/texts/909", "#/texts/910", "#/texts/911", "#/texts/912", "#/texts/913", "#/texts/914", "#/texts/915", "#/texts/916", "#/texts/917", "#/texts/918"], "page_nos": [], "uuid": "03199656-0b66-4b57-8453-6ff3dd766e97"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 29, "source_chunk_idxs": [35], "num_tokens": 412, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nZhou, J.-Q., Zeng, L.-H., Li, C.-T., He, D.-H., Zhao, H.-D., Xu, Y.-N., et al. (2023). Brain organoids are new tool for drug screening of neurological diseases.\nNeural Regen. Res.\n18, 1884-1889. doi: 10.4103/1673-5374.367983\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nZivko, C., Sagar, R., Xydia, A., Lopez-Montes, A., Mintzer, J., Rosenberg, P. B., et al. (2024). iPSC-derived hindbrain organoids to evaluate escitalopram oxalate treatment responses targeting neuropsychiatric symptoms in Alzheimer's disease.\nMol. Psychiatry\n29, 3644-3652. doi: 10.1038/s41380-024-02629-y\nPubMed Abstract\n|\nCrossref Full Text\n|\nGoogle Scholar\nKeywords: Alzheimer's disease, brain organoids, psychedelics, stem cells, neuroplasticity\nCitation: Androni X, Boyd RJ, Rosenberg PB and Mahairaki V (2025) Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.\nFront. Dement\n. 4:1605051. doi: 10.3389/frdem.2025.1605051\nReceived: 02 April 2025; Accepted: 01 July 2025; Published: 04 August 2025.\nEdited by:\nCharbel Moussa\n, Georgetown University, United States\nReviewed by:\nIoannis N. Charalampopoulos\n, University of Crete, Greece", "doc_items_refs": ["#/texts/919", "#/texts/920", "#/texts/921", "#/texts/922", "#/texts/923", "#/texts/924", "#/texts/925", "#/texts/926", "#/texts/927", "#/texts/928", "#/texts/929", "#/texts/930", "#/texts/931", "#/texts/932", "#/texts/933", "#/texts/934", "#/texts/935", "#/texts/936", "#/texts/937", "#/texts/938", "#/texts/939", "#/texts/940", "#/texts/941", "#/texts/942", "#/texts/943", "#/texts/944", "#/texts/945"], "page_nos": [], "uuid": "f5399e2d-4f5e-4faf-a849-94c8966599ab"}
{"doc_id": "2025__Psychedelics_meet_human_brain_organoids_insights_into_proteomics_and_potential_f__W4412883205", "source_path": "<redacted:source_path>", "chunk_id": 30, "source_chunk_idxs": [36, 37], "num_tokens": 469, "text": "Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nReferences\nCopyright \u00a9 2025 Androni, Boyd, Rosenberg and Mahairaki. This is an open-access article distributed under the terms of the\nCreative Commons Attribution License (CC BY)\n. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\n*Correspondence: Vasiliki Mahairaki, dm1hY2hhaTFAamhtaS5lZHU=\nDisclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.\nDownload article\n- Download PDF\n- ReadCube\n- epub\n- XML\nShare on\nExport citation\n- EndNote\n- Reference Manager\n- Simple Text file\n- BibTex\n2,224 Total views 686 Downloads Citation numbers are available from Dimensions\nView article impact\nView altmetric score\nShare on\nEdited by\nC M Charbel  Moussa\nReviewed by\nI N Ioannis  N Charalampopoulos\nTable of contents\n- Abstract\n- 1 Introduction\n- 2 5-MeO-DMT effects\n- 3 LSD effects\n- 4 Discussion\n- Author contributions\n- Funding\n- Acknowledgments\n- Conflict of interest\n- Generative AI statement\n- Publisher's note\n- References\nExport citation\n- EndNote\n- Reference Manager\n- Simple Text file\n- BibTex\nCheck for updates\nFrontiers' impact\n\nPsychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment\nArticles published with Frontiers have received 12 million total citations\nYour research is the real superpower - learn how we maximise its impact through our leading community journals\nExplore our impact metrics\nSupplementary Material\nDownload article\nDownload\n- Download PDF\n- ReadCube\n- epub\n- XML\n- Guidelines\n- Explore\n- Outreach\n- Connect\nFollow us\n\u00a9 2025 Frontiers Media S.A. All rights reserved\nPrivacy policy\n|\nTerms and conditions", "doc_items_refs": ["#/texts/946", "#/texts/947", "#/texts/948", "#/texts/949", "#/texts/950", "#/texts/951", "#/texts/952", "#/texts/953", "#/texts/954", "#/texts/955", "#/texts/956", "#/texts/957", "#/texts/958", "#/texts/959", "#/texts/960", "#/texts/961", "#/texts/962", "#/texts/963", "#/texts/964", "#/texts/965", "#/texts/966", "#/texts/967", "#/texts/968", "#/texts/969", "#/texts/970", "#/texts/971", "#/texts/972", "#/texts/973", "#/texts/974", "#/texts/975", "#/texts/976", "#/texts/977", "#/texts/978", "#/texts/979", "#/texts/980", "#/texts/981", "#/texts/982", "#/texts/983", "#/texts/984", "#/texts/985", "#/texts/986", "#/texts/987", "#/texts/988", "#/texts/989", "#/texts/991", "#/texts/992", "#/texts/993", "#/texts/994", "#/texts/995", "#/texts/996", "#/texts/997", "#/texts/998", "#/texts/999", "#/texts/1000", "#/texts/1001", "#/texts/1002", "#/texts/1003", "#/texts/1004", "#/texts/1005", "#/texts/1006", "#/texts/1007", "#/texts/1008"], "page_nos": [], "uuid": "96064384-587e-4342-b34b-be6af7a05176"}
